Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

Treatment options for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy have recently expanded with the U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitor rucaparib. As more on...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2019
Onderwerpen:
Gynecologic Oncology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964123/
https://ncbi.nlm.nih.gov/pubmed/31575788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0229
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items